Patents Assigned to Taigen Biotechnology Co., Ltd.
-
Publication number: 20240101527Abstract: A compound of Formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof: in which R1, R2, R3, R5, R6, and R7 are defined as in the SUMMARY section. Further disclosed are a method of using the above-described compound, salt, stereoisomer, solvate, or prodrug for treating microbial infections and a pharmaceutical composition containing the same.Type: ApplicationFiled: October 23, 2020Publication date: March 28, 2024Applicant: TAIGEN BIOTECHNOLOGY CO., LTD.Inventors: Chu-Chung Lin, Hung-Chuan Chen, Chiayn Chiang, Chih-Ming Chen
-
Patent number: 11872224Abstract: The present disclosure provides an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.Type: GrantFiled: December 29, 2021Date of Patent: January 16, 2024Assignees: TaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co. (Beijing), Ltd.Inventors: Chi-Feng Yen, Fang-Wei Tien
-
Patent number: 11639349Abstract: Provided is a stereoselective synthesis of an intermediate for the preparation of the heterocyclic derivative as a Cap-dependent endonuclease inhibitor. The synthesis process has the advantages of simple operation, higher yield and relatively controllable steroselectivity, such that it is suitable for large-scale production.Type: GrantFiled: May 27, 2021Date of Patent: May 2, 2023Assignees: TaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co.(Beijing), Ltd.Inventors: Wen-Chang Chen, Han-Pei Hsu, Shan-Yen Chou, Shih-Chieh Chuang, Chi-Feng Yen
-
Publication number: 20230012560Abstract: A compound of Formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof: (I), in which Ra, Rb, Rc, Rd, X1, X2, R1-R4, W, Z, and L are defined as in the SUMMARY section. Further disclosed are a method of using the above-described compound, salt, stereoisomer, solvate, or prodrug for treating HBV infection and a pharmaceutical composition containing same.Type: ApplicationFiled: September 4, 2020Publication date: January 19, 2023Applicant: TAIGEN BIOTECHNOLOGY CO., LTD.Inventors: Chih-Ming Chen, Chu-Chung Lin, Chang-Pin Huang, Chiayn Chiang
-
Patent number: 10596171Abstract: Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5?R6? or NR7?; each of R1, R2, R2?, R3, R3?, R4, R5, R5?, R6, R6?, R7, and R7?, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5? and R6?, or R5 and R5?, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.Type: GrantFiled: January 18, 2019Date of Patent: March 24, 2020Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Chu-Chung Lin, Hung-Chuan Chen, Chiayn Chiang, Chi-Feng Yen, Ming-Chu Hsu
-
Patent number: 10377714Abstract: A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which R1 is C1-C5 alkyl or C3-C5 cycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.Type: GrantFiled: August 11, 2017Date of Patent: August 13, 2019Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Shan-Yen Chou, Wen-Chang Chen, Chi-Feng Yen, Han-Pei Hsu, Ming-Chu Hsu, Chu-Chung Lin
-
Patent number: 10004719Abstract: A spray-dried solid dispersion containing a pharmaceutical compound of formula (I) shown below and a pharmaceutically acceptable polymer, in which the pharmaceutical compound is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing such a solid dispersion and using it for treating hepatitis C virus infection and a pharmaceutical formulation containing same.Type: GrantFiled: May 30, 2017Date of Patent: June 26, 2018Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Ming-Chu Hsu, Chu-Chung Lin, Chi-Hsin Richard King
-
Patent number: 9375406Abstract: A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification): The method can be used to treat cancer and myocardial infarction.Type: GrantFiled: September 30, 2014Date of Patent: June 28, 2016Assignee: Taigen Biotechnology Co., Ltd.Inventors: Ming-Chu Hsu, Ying-Huey Huang, Chi-Feng Yen, Chi-Hsin Richard King
-
Patent number: 9023834Abstract: This invention relates to a pharmaceutical kit containing a lyophilized preparation of a pyrimidine compound described in the specification. Also disclosed is a lyophilization process for making this preparation.Type: GrantFiled: November 12, 2009Date of Patent: May 5, 2015Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Chi-Feng Yen, Judy Yuan, Chi-Hsin Richard King
-
Patent number: 8389560Abstract: This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.Type: GrantFiled: September 15, 2009Date of Patent: March 5, 2013Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Chen-Fu Liu, Kuang-Yuan Lee, Pei-Chin Cheng, Yo-Chin Liu, Pin Lo, Kuo-Feng Tseng, Chih-Ming Chen, Chi-Hsin Richard King, Chu-Chung Lin
-
Patent number: 8372849Abstract: This invention relates to heterocyclic compounds of the formulas shown in the specification. It also relates to methods for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, and tissue injuries with one of the heterocyclic compounds.Type: GrantFiled: November 3, 2008Date of Patent: February 12, 2013Assignee: Taigen Biotechnology Co., Ltd.Inventors: Chi-Feng Yen, Cheng-Kung Hu, Chang-Pin Huang, Ying-Huey Huang, Gholam Hossein Hakimelahi, Chi-Hsin Richard King
-
Patent number: 8211909Abstract: This invention relates to a method of treating infection by methicillin-nonsusceptibale bacteria, vancomycin-nonsusceptibale bacteria, penicillin-nonsusceptibale bacteria, clarithromycin-nonsusceptibale bacteria, or metronidazole-nonsusceptibale bacteria by administering to a subject in need thereof an effective amount of a compound of the following formula:Type: GrantFiled: September 8, 2008Date of Patent: July 3, 2012Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Ming-Chu Hsu, Chi-Hsin Richard King, Shu-Jen Chen, Luke Lin
-
Patent number: 8193206Abstract: This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.Type: GrantFiled: December 8, 2008Date of Patent: June 5, 2012Assignee: TaiGen Biotechnology Co., Ltd.Inventors: Chi-Feng Yen, Cheng-Kung Hu, Ming-Chen Chou, Chen-Tso Tseng, Chien-Huang Wu, Ying-Huey Huang, Shu-Jen Chen, Chi-Hsin Richard King
-
Patent number: 8158798Abstract: Process for making 7-cycloamino-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids. Borate ester compounds suitable for use in such process.Type: GrantFiled: October 27, 2008Date of Patent: April 17, 2012Assignee: TaiGen Biotechnology Co., Ltd.Inventor: Michael Reilly
-
Publication number: 20110178107Abstract: This invention relates to compounds of Formula (I), (II), or (III) shown in the specification. These compounds can be used to treat hepatitis C virus infection.Type: ApplicationFiled: January 19, 2011Publication date: July 21, 2011Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Ching-Cheng Wang, Chen-Fu Liu, Kuang-Yuan Lee, Mei-Chun Lin, Shu-Huei Wang, Chi-Feng Yen, Yu-Hsuan Wang, Chi-Hsin Richard King
-
Publication number: 20110065737Abstract: This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.Type: ApplicationFiled: September 15, 2009Publication date: March 17, 2011Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Chen-Fu Liu, Kuang-Yuan Lee, Pei-Chin Cheng, Yo-Chin Liu, Pin Lo, Kuo-Feng Tseng, Chih-Ming Chen, Chi-Hsin Richard King, Chu-Chung Lin
-
Publication number: 20100152452Abstract: This invention relates to dialdehyde or dinitrile compounds, which are useful for stereoselective synthesis of piperidine, pyrrolidine, and azepane derivatives.Type: ApplicationFiled: December 14, 2009Publication date: June 17, 2010Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Shan-Yen Chou, Chi-Hsin Richard King
-
Publication number: 20100120719Abstract: This invention relates to a pharmaceutical kit containing a lyophilized preparation of a pyrimidine compound described in the specification. Also disclosed is a lyophilization process for making this preparation.Type: ApplicationFiled: November 12, 2009Publication date: May 13, 2010Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Chi-Feng Yen, Judy Yuan, Chi-Hsin Richard King
-
Publication number: 20100041697Abstract: This invention relates to a method of treating pneumonia by orally administering to a subject in need thereof a quinolone compound of formula (I), shown in the disclosure, at a daily dose of 2-30 mg/kg.Type: ApplicationFiled: July 1, 2009Publication date: February 18, 2010Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Kit Chiu, Luke Lin, Hao-Chen Tan, Chi-Hsin Richard King, Ming-Chu Hsu
-
Publication number: 20100004282Abstract: This invention relates to a method of treating infection by methicillin-nonsusceptibale bacteria, vancomycin-nonsusceptibale bacteria, penicillin-nonsusceptibale bacteria, clarithromycin-nonsusceptibale bacteria, or metronidazole-nonsusceptibale bacteria by administering to a subject in need thereof an effective amount of a compound of the following formula:Type: ApplicationFiled: September 8, 2008Publication date: January 7, 2010Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Ming-Chu Hsu, Chi-Hsin Richard King, Shu-Jen Chen, Luke Lin